Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ)
CNY 23.75
(-0.88%)
CNY 23.75
(-0.88%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 487.62 Million CNY | -59.26% |
| 2022 | 1.19 Billion CNY | 88.68% |
| 2021 | 634.43 Million CNY | 0.04% |
| 2020 | 634.17 Million CNY | 63.67% |
| 2019 | 387.46 Million CNY | 25.9% |
| 2018 | 307.74 Million CNY | 46.06% |
| 2017 | 210.69 Million CNY | 45.32% |
| 2016 | 144.98 Million CNY | 15.66% |
| 2015 | 125.35 Million CNY | 27.44% |
| 2014 | 98.36 Million CNY | 66.71% |
| 2013 | 59 Million CNY | 55.65% |
| 2012 | 37.9 Million CNY | 19.69% |
| 2011 | 31.67 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 80.13 Million CNY | -41.71% |
| 2024 Q2 | 137.46 Million CNY | -37.04% |
| 2024 Q1 | 218.33 Million CNY | 148.63% |
| 2023 FY | 487.62 Million CNY | -59.26% |
| 2023 Q1 | 203.67 Million CNY | 557.62% |
| 2023 Q4 | 87.81 Million CNY | 34.46% |
| 2023 Q2 | 130.82 Million CNY | -35.77% |
| 2023 Q3 | 65.3 Million CNY | -50.08% |
| 2022 Q2 | 274.38 Million CNY | -69.63% |
| 2022 Q1 | 903.5 Million CNY | 12454.61% |
| 2022 Q4 | -44.5 Million CNY | -171.82% |
| 2022 Q3 | 61.97 Million CNY | -77.41% |
| 2022 FY | 1.19 Billion CNY | 88.68% |
| 2021 Q4 | 7.19 Million CNY | -89.94% |
| 2021 Q1 | 155.42 Million CNY | 127.81% |
| 2021 Q2 | 400.24 Million CNY | 157.52% |
| 2021 FY | 634.43 Million CNY | 0.04% |
| 2021 Q3 | 71.56 Million CNY | -82.12% |
| 2020 Q3 | 116.94 Million CNY | -66.7% |
| 2020 Q2 | 351.15 Million CNY | 258.88% |
| 2020 Q1 | 97.84 Million CNY | 0.57% |
| 2020 FY | 634.17 Million CNY | 63.67% |
| 2020 Q4 | 68.22 Million CNY | -41.66% |
| 2019 Q3 | 83.66 Million CNY | -37.54% |
| 2019 Q2 | 133.93 Million CNY | 84.55% |
| 2019 FY | 387.46 Million CNY | 25.9% |
| 2019 Q4 | 97.29 Million CNY | 16.29% |
| 2019 Q1 | 72.57 Million CNY | -14.9% |
| 2018 Q3 | 60.37 Million CNY | -43.53% |
| 2018 Q2 | 106.9 Million CNY | 93.71% |
| 2018 Q1 | 55.18 Million CNY | -4.2% |
| 2018 FY | 307.74 Million CNY | 46.06% |
| 2018 Q4 | 85.28 Million CNY | 41.26% |
| 2017 Q4 | 57.6 Million CNY | 31.41% |
| 2017 Q1 | 35.14 Million CNY | 27.54% |
| 2017 Q2 | 74.1 Million CNY | 110.87% |
| 2017 FY | 210.69 Million CNY | 45.32% |
| 2017 Q3 | 43.83 Million CNY | -40.84% |
| 2016 FY | 144.98 Million CNY | 15.66% |
| 2016 Q4 | 27.55 Million CNY | -25.7% |
| 2016 Q3 | 37.08 Million CNY | -31.59% |
| 2016 Q2 | 54.2 Million CNY | 107.37% |
| 2016 Q1 | 26.14 Million CNY | -34.8% |
| 2015 FY | 125.35 Million CNY | 27.44% |
| 2015 Q4 | 40.09 Million CNY | 49.85% |
| 2015 Q3 | 26.75 Million CNY | -30.19% |
| 2015 Q2 | 38.32 Million CNY | 89.99% |
| 2015 Q1 | 20.17 Million CNY | -4.11% |
| 2014 Q1 | 22.27 Million CNY | 0.0% |
| 2014 Q4 | 21.03 Million CNY | -18.79% |
| 2014 Q3 | 25.9 Million CNY | -11.11% |
| 2014 Q2 | 29.14 Million CNY | 30.83% |
| 2014 FY | 98.36 Million CNY | 66.71% |
| 2013 FY | 59 Million CNY | 55.65% |
| 2012 FY | 37.9 Million CNY | 19.69% |
| 2011 FY | 31.67 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 307.46 Million CNY | -58.597% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.02 Billion CNY | 75.918% |
| Dirui Industrial Co.,Ltd. | 275.58 Million CNY | -76.939% |
| Beijing Strong Biotechnologies, Inc. | 523.74 Million CNY | 6.896% |
| Medicalsystem Biotechnology Co., Ltd. | 256.55 Million CNY | -90.069% |
| Maccura Biotechnology Co.Ltd | 312.61 Million CNY | -55.981% |
| Guangdong Hybribio Biotech Co.,Ltd. | 140.47 Million CNY | -247.133% |
| BGI Genomics Co., Ltd. | 92.9 Million CNY | -424.89% |
| Amoy Diagnostics Co., Ltd. | 261.48 Million CNY | -86.483% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -141.59 Million CNY | 444.389% |